The role of leukotrienes in the pathogenesis of inflammation in patients with different phenotypes of bronchial asthma and chronic obstructive pulmonary disease


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Leukotrienes (LT) are involved in the pathogenesis of inflammation in bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD). LT is a metabolic product of arachidonic acid. There are cystenyl (C4, D4, E4) and dihydroxyl (B4) LT. LT C4, D4, E4 have a powerful bronchoconstrictor effect, LT B4 serves as a chemoattractant for neutrophils. Objective. Comparative assessment of the role of LT in patients with different phenotypes of BA and COPD. Methods. Four groups of patients were examined: 1st (n=57) - patients with allergic BA (ABA), 2nd (n=68) - patients with non-allergic BA (NABA), 3rd (n=43) - patients with aspirin-induced asthma (AIBA), group 4 (n=65) - patients with COPD. Results. A high total LT C4, D4, E4 level was observed in patients with ABA, to a lesser extent in AIBA compared to their values in patients with NABA, COPD and the control group. LT B4 values were significantly increased in patients with AIBA and COPD compared with ABA, NABA and the control group. There was a statistically significant positive correlation of total LT C4, D4, E4 with the blood eosinophil number (r=0.62, p<0.05) and with the eosinophilic type of inflammation (r=0.70, p<0.05). There was a correlation between LT B4 and neutrophils (r=0.52, p<0.05) and neutrophilic type of inflammation (r=0.56, p<0.05). Conclusion. LT plays an important role in the pathogenesis of airway inflammation in BA and COPD. In the pathogenesis of eosinophilic inflammation in ABA, total LT C4, D4, E4 prevail. LT B4 plays a significant role in neutrophilic inflammation in NABA and COPD. AIBA is characterized by a mixed type of inflammation (eosinophilic-neutrophilic), with increased level of both total LT C4, D4, E4, and LT B4. Thus, LT can be considered as markers of types of inflammation. Clarification of the types of inflammation will make it possible to personalize therapy and increase the effectiveness of treatment of patients with BA and COPD.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Kostina

Penza Institute for Advanced Medical Education - Branch of the Russian Medical Academy of Continuous Professional Education

Penza, Russia

E. Trushina

Penza Institute for Advanced Medical Education - Branch of the Russian Medical Academy of Continuous Professional Education

Email: tiushina.lena@mail.ru
Teaching Assistant at the Department of Pulmonology and Phthisiology 8A, Stasova str., Penza 440060, Russian Federation

E. Orlova

Penza Institute for Advanced Medical Education - Branch of the Russian Medical Academy of Continuous Professional Education

Penza, Russia

N. Baranova

Penza Institute for Advanced Medical Education - Branch of the Russian Medical Academy of Continuous Professional Education

Penza, Russia

O. Levashova

Penza State University

Penza, Russia

Әдебиет тізімі

  1. Byrne P.M. Lukotrienes in the pathogenesis of asthma. Chest. 1997;111(2):27-34.
  2. Gupta G, Jatana S.K., Wilson C.G. Anti-leukotrienes in Childhood Asthma. Med J Armed Forces India. 2002;58(3):242-46. Doi: 10.1016/ S0377-1237(02)80139-3.
  3. Drakatos P, Lykouras D., Sampsonas F., et al. Targeting leukotrienes for the treatment of COPD? Inflamm. Allergy Drug Targets. 2009;8(4):297-306. doi: 10.2174/187152809789352177.
  4. Wan M, Tang X., Stsiapanava A., Haeggstrom J.Z. Biosynthesis of leukotriene B(4). Semin Immunol. 2017;33:3-15. doi: 10.1016/j.smim.2017.07.012.
  5. McMillan R.M. Leukotrienes in respiratory disease. Paediatr Respir Rev. 2001;2(3):238-44. doi: 10.1053/prrv.2001.0146.
  6. Fal A.M., Kopec A. [Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment]. Pneumonol Alergol Pol. 2010;78(1):68-73.
  7. Williams A.N., Simon R.A., Woessner K.M., Stevenson D.D. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120(2):273- 77. Doi: 10.1016/j. jaci.2007.03.020.
  8. Szczeklik A., Nizankowska E., Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-induced Asthma. Eur Respir J. 2000;16:432-36.
  9. Cingi C, Muluk N.B., I pci K., Sahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015;15(11):64. Doi: 10.1007/ s11882-015-0564-7.
  10. Li K.L., Lee A.Y., Abuzeid W.M. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management. Med Sci (Basel). 2019;7(3):45. Doi: 10.3390/ medsci7030045.
  11. Antczak A., Montuschi P, Kharitonov S., et al. Increased Exhaled Cysteinyl-Leukotrienes and 8-isoprostane in Aspirin-Induced Asthma. Am J Respir Crit Care Med. 2002;166(3):301-6. doi: 10.1164/rccm.2101021.
  12. Chaumphol P, Sritipsukho P, Manochantr S., Kiatpunsodsai S. Urinary Leukotriene E4 Level in Non-Allergic Thai Young Children. J Med Assoc Thai. 2015;98(3):29-33.
  13. Malaviya R., Abraham S.N. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol. 2000;67(6):841-46. Doi: 10.1002/ jlb.67.6.841.
  14. Crooks S.W., Bayley D.L., Hill S.L., Stockley R.A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 2000;15(2):274-80. doi: 10.1034/j.1399-3003.2000.15b09.x.
  15. McDonald V.M., Higgins I., Wood L.G., Gibson P.G. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;6(7):691-94.
  16. O'Byrne P.M. Leukotrienes in the pathogenesis of asthma. Chest. 1997;111(2):27-34. doi: 10.1378/chest.111.2_supplement.27s.
  17. Larsson K. Inflammatory markers in COPD. Clin Respir J. 2008;2(1):84-7. doi: 10.1111/j.1752-699X.2008.00089.x.
  18. Beeh K.M., Kornmann O., Buhl R., et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003;123(4):1240-47. Doi: 10.1378/ chest.123.4.1240.
  19. Ding Y.L., Yao W.Z., Zheng J., et al. Changes of leukotriene B4 in chronic obstructive pulmonary disease and effects of theophylline on leukotriene B4. Beijing Da Xue Xue Bao Yi Xue Ban. 2005;37(4):393-97.
  20. Profita M., Giorgi R.D., Sala A., et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005;60(11):1361-69. doi: 10.1111/j.1398-9995.2005.00892.x.
  21. Dong R., Xie L., Zhao K., et al. Cigarette smoke-induced lung inflammation in COPD mediated via LTB4/BLT1/SOCS1 pathway. Int J Chron Obstruct Pulmon Dis. 2015;11:31-41.
  22. Liu M., Yokomizo T. The role of leukotrienes in allergic diseases. Allergol Int. 2015;64(1):17-26. doi: 10.1016/j.alit.2014.09.001.
  23. Bachert C., Zhang N., Patou J., et al. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol. 2008;8(1):34-8.
  24. Juergens U.R., Christiansen S.C., Stevenson D.D., Zuraw B.L. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol. 1995;96:148e56.
  25. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention (GOLD). National Institutes of Health; National Heart, Lung, and Blood Institute. Updated 2014. URL: https:// goldcopd.org/wpcontent/uploads/2016/04/ GOLD_Report_Russian_2014.pdf
  26. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (GINA). National Institutes of Health; National Heart, Lung, and Blood Institute. Updated 2014. URL: http://www. doctorbeketov.ru/data/documents/Bronhialnaya-astma-GYNA-2014-russkaya-versiya.pdf
  27. Гланц С. Медико-биологическая статистика. М.: Практика, 1999. [Glanc S. Medical biological statistics. M.: Praktika, 1999. (In Russ.)].
  28. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
  29. Lindsay M.A.,Perkins R.S.,Barnes P.J.,Giembycz M.A. Leukotriene B4 activates the NADPH oxidase in eosinophils by a pertussis toxin-sensitive mechanism that is largely independent of arachidonic acid mobilization. J Immunol. 1998;160:4526-34.
  30. Ohnishi H., Miyahara N., Gelfand E.W. The role of leukotriene B(4) in allergic diseases. Allergol Int. 2008;57(4):291-98. Doi: 10.2332/ allergolint.08-RAI-0019.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>